Start with what life feels like now
Neuregen’s regenerative and biologic care is designed for people exploring options for persistent pain, tissue problems or barriers to rehabilitation. We consider selected procedures alongside your functional goals, explain the evidence for each use and distinguish clinical options from investigational research.
How we look at the whole picture
You plan your day around how long you can sit, stand or walk before pain takes over.
You have tried to keep going, but a sore neck, back or joint keeps bringing you back to the same limits.
You do not need to know which treatment to ask for. Start with what has changed and what you want to be able to do again.
The 7 Domains of Recovery™
Pain, joint stability, nervous-system regulation and activity tolerance can affect rehabilitation together. The 7 Domains of Recovery™ help place a proposed intervention within that wider picture. We ask what it may address, what remains uncertain and what rehabilitation or other care should happen around it.
Neuregen's proprietary 7 Domains of Recovery framework organizes that conversation around seven connected parts of your life and health. We consider all seven, then focus the evaluation on the questions your history raises.
Explore our clinical frameworkWhat has changed in your memory, concentration, balance or sensory tolerance?
What happens when you stand, move, rest or encounter stress?
What immune history, reactions or symptoms need a closer look?
What affects your energy through the day and after activity?
How do pain, posture, movement and stability affect what you can do?
How are mood, stress and patterns of coping affecting your day?
What demands, relationships and support shape your recovery?
Domains most involved:
These guide the evaluation; they do not mean every domain needs treatment.
We review the pattern of pain, the examination and any relevant prior imaging. We agree on a functional goal, such as sitting through a meal or walking farther, before choosing care.
01
We start with what has changed, what you have tried, and the activities you most want to return to.
02
We review prior reports and select relevant assessments. You should understand what each assessment is meant to clarify.
03
We discuss the findings, possible approaches, costs and practical constraints. The plan sets an order that fits your situation.
04
We compare your response with the starting point, including daily function. If something is not helping, we discuss what needs to change.
Only then do we discuss which therapies, if any, belong in your plan. The choice depends on the findings, the evidence, your preferences and how you respond.
Talk through your situationWe use established medicine where it works, and emerging medicine where it makes sense.
These are options to discuss after evaluation, not a predetermined treatment plan. Evidence is shown on each therapy’s own page, matched to the condition it is being used for, because the same therapy can have different evidence for different conditions. An evidence label does not mean FDA approval.
Brain-recovery applications; educational discussion does not establish availability.
Brain-recovery applications; product-specific benefit and safety are not established.
Research purposes only; not a clinical treatment offered here.
Localized healing signals at sites of tissue damage or neurogenic inflammation; image guidance required for accuracy
Peripheral nerve sensitization and neurogenic inflammation; distinct technique from standard prolotherapy
Investigational for brain recovery; proposed mechanisms do not establish clinical benefit or regulatory authorization
Investigational uses with limited safety and benefit data; product-specific regulatory review is required
Investigational; benefit and safety for the proposed use are not established
Red and near-infrared light for tissue and transcranial applications; adjunct to rehabilitation
Pulsed electromagnetic field and electrical stimulation to reduce pain and support tissue recovery
Lab-directed nutrient and hydration infusions coordinated with the plan; never a standalone menu
Image-guided regenerative injections paired with a graded stability program for chronic low-back and nerve pain
Rehabilitation support
Ultrasound-guided PRP (platelet-rich plasma) and neural prolotherapy — clinician-administered, image-guided, and targeted at structural tissue damage and peripheral nerve sensitization. Applied within a rehabilitation plan, not as standalone procedures.
Injection therapy detailsRehabilitation support
A structured program for chronic low-back and post-surgical nerve pain: image-guided PRP and prolotherapy, neural hydrodissection where a nerve is entrapped, and a graded stability program that continues between and after injection visits.
Low back program detailsRehabilitation support
Low-level laser and red or near-infrared light applied to tissue and, transcranially, to the brain to support cellular energy production. Used as an adjunct to rehabilitation, with transcranial use labeled emerging.
Photobiomodulation detailsRehabilitation support
Pulsed electromagnetic field therapy and electrical stimulation (TENS, NMES) used to reduce pain and muscle guarding so rehabilitation can proceed. PEMF is FDA-cleared for bone healing; its neurologic uses are emerging.
PEMF and electric modality detailsRehabilitation support
Nutrient and hydration infusions prescribed from your labs and coordinated with the rest of your plan. There is no drip menu; the formulation follows the assessment.
IV therapy detailsRehabilitation support
Peptides belong within regenerative and biologic care, alongside discussion of PRP, exosomes and cellular therapies. Research into neural repair does not establish that a peptide improves symptoms or is safe for a particular patient. These uses are investigational; we review the specific product, clinical evidence, risks, alternatives and regulatory status. Inclusion here is educational and does not confirm availability.
Compounded peptide medicines are not FDA approved. Informed consent does not replace required regulatory authorization.
Research & Brain Rehabilitation
We follow research with a practical question: could an approach help someone participate in rehabilitation or regain meaningful function? A promising laboratory mechanism is a starting point for research. Patient benefit, safety and appropriate regulatory authorization need their own evidence.
Researchers are studying whether specific cell products may support repair after neurologic injury. Cell source, preparation, dose and condition matter; results for one product cannot be transferred to another. Brain-recovery applications discussed here remain investigational.
FDA: stem-cell and regenerative products →Exosomes carry signals between cells. Research explores whether these signals may support recovery, but proposed mechanisms do not establish clinical benefit for brain rehabilitation. There are no FDA-approved exosome products; product-specific safety and efficacy remain essential unanswered questions.
FDA: exosome products →MUSE cells are a distinct area of cell research. A small randomized trial studied the CL2020 product after ischemic stroke and reported an early signal of possible benefit, alongside adverse events. It does not establish routine use for brain recovery, dementia or other conditions. MUSE cells are discussed here for research purposes only, not as a treatment offered by Neuregen.
Read the CL2020 stroke trial →Our Commitment to Transparency
Regenerative injection therapies carry emerging evidence for the musculoskeletal and neurogenic pain applications used here. Peptide protocols carry investigational status for neuroprotective and anti-inflammatory indications. Evidence is labeled on each tool.
Regulatory and safety information about unapproved regenerative products. This is a disclosure source, not evidence that a product benefits a particular condition.
Each level describes the evidence for a particular treatment and use. It does not guarantee a specific outcome or indicate FDA approval.
| Level | Label | What It Means |
|---|---|---|
| Level 1 | Strong | Multiple high-quality studies consistently support meaningful benefit for this use. |
| Level 2 | Moderate | Good clinical evidence supports benefit, but important uncertainty remains. |
| Level 3 | Emerging | Early clinical evidence suggests potential benefit, but is not yet strong or consistent. |
| Level 4 | Preliminary | Evidence is limited to small studies, observational data or indirect clinical evidence. |
| Level 5 | Investigational | There is a rationale or very early evidence, but clinical benefit has not been established. |
We explain the proposed care, alternatives and fees before treatment. Your written estimate follows your individual plan. Neuregen is an out-of-network specialty clinic.
The training behind this care
Neuregen considers regenerative options within a rehabilitation plan, with condition-specific evidence labels and upfront discussion of experimental status. The purpose is to decide whether an option belongs in your care at all.
Dr. David George: Board certifications and training in functional neurology, integrative psychiatry, and mental health; certified brain injury specialist.
Training most relevant to this area
These are the founder’s qualifications. We confirm the treating clinician and their role when discussing your plan.
See Dr. George’s full credentialsmodality
No. Blood-derived preparations, cell products, exosomes and peptides are different approaches. Findings for one product or condition do not establish the safety or benefit of another.
We consider whether a proposed option addresses a relevant barrier to function or participation in rehabilitation. Evidence for a joint or tendon application does not establish an effect on memory or brain recovery.
They remain investigational for the brain-recovery uses discussed here. MUSE cells are presented for research purposes only. Educational discussion does not mean a product is approved, offered by Neuregen or appropriate for you.
Ask about the specific product and target, evidence for that use, regulatory status, risks, alternatives and total fees. The proposed plan should also explain how progress will be measured and when the approach would change.
Regenerative injections at Neuregen include ultrasound-guided PRP (platelet-rich plasma) and neural prolotherapy, also called perineural injection therapy. PRP concentrates growth factors and healing signals from the patient's own blood and delivers them under image guidance to a target site. Neural prolotherapy targets peripheral nerve sensitization and neurogenic inflammation at the tissue level — it is a distinct technique that requires specific training and is different from standard prolotherapy.
Regenerative injection therapies carry emerging evidence — promising clinical evidence and active investigation, but not yet a standard of care for the specific indications used here. Neuregen does not claim established outcomes; it offers these therapies with honest evidence labeling, physician oversight, and integration into a broader rehabilitation plan.
Peptides are short chains of amino acids. Neural-repair uses discussed here, including research involving Cerebrolysin, BPC-157, Epitalon, Semax and Selank, remain investigational. Proposed mechanisms do not establish benefit or safety. Compounded products are not FDA approved, and a specific product may have additional regulatory restrictions. We discuss evidence and alternatives; a listing does not confirm availability.
Peptides are a broad class, and their actions differ by molecule. A peptide label does not establish how a product works, whether it affects hormone pathways, or whether it is safe or effective. Ask about the exact agent and proposed indication rather than treating peptides as interchangeable.
No. Regenerative therapies at Neuregen are integrated into a structured rehabilitation plan — applied after the assessment identifies specific biological targets, and coordinated with the broader program. They are tools within the clinical integration platform, not isolated procedures. Offering these therapies without the surrounding rehabilitation context would reduce their effectiveness.
Candidacy is determined after a full clinical review by our clinical team. Regenerative injections are considered for individuals with structural contributors to nervous-system symptoms, complex pain syndromes with a neurogenic component, and musculoskeletal pathology affecting recovery. Peptide protocols are considered for patients with neuroinflammatory, neuroregenerative, or metabolic deficits identified in the assessment.
Persistent pain or reduced function may already be changing how you spend your days. A consultation can help you compare options and unanswered questions; there is no deadline to choose an experimental treatment.
8090 N. 85th Way, Suite 100, Scottsdale, AZ 85258 · Mon–Thu, 9:00 AM – 5:30 PM